“Female Viagra” Approved by the FDA – How Safe Is This?

The U.S drug regulator has approved on Friday the drug from Palatin Technologies and Amag Pharmaceuticals. This drug means to restore the sexual desire in those women who are in the stage of premenopause. It is also called the “female Viagra.”

This is supposed to compete in a market that has failed horribly. Researchers said that a drug that could treat the loss of sexual desire in women in a safe way could reach sales of about $1 billion in a year. The shares from Palatin jumped to 44%, and the share from Amag rose to 11.5%.

They have in their composition Vyleesi, which is known as bremelanotide. It can activate some paths in the brain that involve sexual desire. It can help premenopausal women that suffer from HSDD (the hypoactive sexual desire disorder).

Addyi vs. Vyleesi: which one is better?

This drug will compete with Sprout Pharmaceuticals’ Addyi, which is a pill that needs to be taken once a day, and that was approved for HSDD in 2015. However, women taking this pill were not allowed to drink alcohol while they were on medication. The drug will be available starting with September, and it will be found in select pharmacies.

Addyi was approved due to the pressure from advocacy groups. However, the reviews from the FDA (Food and Drug Administration) cataloged it to be unsafe and not entirely useful.

Vyleesi does not have a problem with alcohol, and it actually has many advantages, more than Addyi has. It comes to tolerable side effects, and women do not have to take the pill every day.

During clinical trials, some side effects could be observed, such as mild to moderate nausea, which lasted about two hours, and it only happened over the first three doses. It is worth mentioning that 40% of the patients from this clinical trial had experienced side effects such as nausea.

Recommended For You

Meagan Kozlovs

About the Author: Meagan Kozlovs

Meagan Kozlovs is a reporter for Debate Report. She’s worked and interned at Global News Toronto  and CHECX. Megan is based in Toronto and covers issues affecting her city. In addition to her severe milk shake addiction, she’s a Netflix enthusiast, a red wine drinker, and a voracious reader.

Leave a Reply

Your email address will not be published. Required fields are marked *